Evidence map›Paper›PMID 38015382›Full record

ArticleJournal of cancer survivorship : research and practice2025

Barriers and facilitators to the implementation of a new European eHealth solution (SurPass v2.0): the PanCareSurPass Open Space study.

Ismay A E de Beijer, Emma C Hardijzer, Riccardo Haupt, Desiree Grabow, Julia Balaguer, Edit Bardi, Adela Cañete Nieto, Audronė Ciesiūniene, Vanessa Düster, Anna-Liesa Filbert and 15 more

Erratum issuedAbstract read
In one paragraph

Article in Journal of cancer survivorship : research and practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

25 authors.

Ismay A E de BeijerPrincess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, The Netherlands. i.a.e.debeijer-3@prinsesmaximacentrum.nl.
Emma C HardijzerPrincess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, The Netherlands.
Riccardo HauptIRCCS Istituto Giannina Gaslini, Genoa, Italy.
Desiree GrabowDivision of Childhood Cancer Epidemiology, German Childhood Cancer Registry, Institute of Medical Biostatistics, Epidemiology and Informatics (IMBEI), University Medical Center, of the Johannes Gutenberg University Mainz, Mainz, Germany.
Julia BalaguerHospital Universitario y Politécnico La Fe, Valencia, Spain.
Edit BardiSt. Anna Children's Hospital, Vienna, Austria.
Adela Cañete NietoHospital Universitario y Politécnico La Fe, Valencia, Spain.
Audronė CiesiūnieneVilnius University Hospital Santaros Klinikos, Vilnius, Lithuania.
Vanessa DüsterSt. Anna Children's Hospital and Children's Cancer Research Institute, Department of Studies and Statistics for Integrated Research and Projects, Department of Paediatrics, Medical University of Vienna, Vienna, Austria.
Anna-Liesa FilbertDivision of Childhood Cancer Epidemiology, German Childhood Cancer Registry, Institute of Medical Biostatistics, Epidemiology and Informatics (IMBEI), University Medical Center, of the Johannes Gutenberg University Mainz, Mainz, Germany.
Hannah GsellCCI Europe, Vienna, Austria.
Monika KapitančukėVilnius University Hospital Santaros Klinikos, Vilnius, Lithuania.
Ruth LadensteinSt. Anna Children's Hospital and Children's Cancer Research Institute, Department of Studies and Statistics for Integrated Research and Projects, Department of Paediatrics, Medical University of Vienna, Vienna, Austria.
Thorsten LangerUniversitatsklinikum Schleswig-Holstein, Campus Lubeck, Lübeck, Germany.
Monica MuracaIRCCS Istituto Giannina Gaslini, Genoa, Italy.
Selina R van den OeverPrincess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, The Netherlands.
Sofie PrikkenUniversity Hospitals Leuven, KU Leuven, Louvain, Belgium.
Jelena RasconVilnius University Hospital Santaros Klinikos, Vilnius, Lithuania.
Maria Teresa TormoInstituto de Investigación Sanitaria La Fe, Valencia, Spain.
Anne UyttebroeckUniversity Hospitals Leuven, KU Leuven, Louvain, Belgium.
Gertrui VercruysseUniversity Hospitals Leuven, KU Leuven, Louvain, Belgium.
Helena J H van der PalPrincess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, The Netherlands.
Leontien C M KremerPrincess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, The Netherlands.
Saskia M F PluijmPrincess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, The Netherlands.
PanCareSurPass consortium

Funding

Horizon 2020 899999
6 · The paper itself

Abstract

purposeTo identify barriers and facilitators for implementing the Survivorship Passport (SurPass) v2.0 in six long-term follow-up (LTFU) care centres in Europe.

methodsStakeholders including childhood cancer survivors (CCSs), healthcare providers (HCPs), managers, information and technology (IT) specialists, and others, participated in six online Open Space meetings. Topics related to Care, Ethical, Legal, Social, Economic, and Information & IT-related aspects of implementing SurPass were evaluated.

resultsThe study identified 115 barriers and 159 facilitators. The main barriers included the lack of standardised LTFU care in centres and network cooperation, uncertainty about SurPass accessibility, and uncertainty about how to integrate SurPass into electronic health information systems. The main facilitators included standardised and coordinated LTFU care in centres, allowing CCSs to conceal sensitive information in SurPass and (semi)automatic data transfer and filing.

conclusionsKey barriers to SurPass implementation were identified in the areas of care, ethical considerations, and information & IT. To address these barriers and facilitate the implementation on SurPass, we have formulated 27 recommendations. Key recommendations include using the internationally developed protocols and guidelines to implement LTFU care, making clear decisions about which parties have access to SurPass data in accordance with CCSs, and facilitating (semi)automated data transfer and filing using Health Level 7 (HL7) Fast Healthcare Interoperability Resources (FHIR). IMPLICATIONS FOR CANCER SURVIVORS: The findings of this study can help to implement SurPass and to ensure that cancer survivors receive high-quality LTFU care with access to the necessary information to manage their health effectively.

Indexed as

Cancer SurvivorsNeoplasmsTelemedicineEuropeHealth PersonnelHumanseHealthLong-term follow-up careOpen Space TechnologyPaediatric oncologySurPassSurvivorship careSurvivorship Passport

Identifiers

PMID38015382
PMCPMC11926050

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.